Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

Company Overview - Windward Bio is a clinical-stage drug development company focused on improving outcomes for advanced immunological diseases, with an initial focus on severe respiratory conditions [8] - The company is led by a highly experienced team of biopharmaceutical executives with a track record of 15+ product launches, 2 Nasdaq IPOs, and 2 major sales (Therachon to Pfizer for $810M and VectivBio to Ironwood for$1.2B) [3] - Windward Bio has secured $200M in Series A financing led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, with co-investment from SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners [1] Product Pipeline - WIN378 is a potential best-in-class, long-acting monoclonal antibody targeting the TSLP ligand, with dosing every 6 months, currently preparing for Phase 2 trials in severe asthma with initial clinical readouts expected in 2026 [2][6] - The company is building a discovery pipeline of long-acting bispecifics leveraging validated targets and synergistic biology, with Series A financing supporting the advancement of 2 undisclosed programs through IND-enabling studies [4][7] - WIN378 has been engineered for extended half-life and effector silencing, administered subcutaneously, and has shown benefits in inflammatory phenotypes for asthma and COPD [6] Strategic Partnerships - Windward Bio has licensed WIN378 from Kelun-Biotech and Harbour BioMed for global rights, excluding China and select smaller Asian markets [1] - Harbour BioMed, a global biopharmaceutical company, focuses on novel antibody therapeutics in immunology and oncology, utilizing proprietary antibody technology platforms like Harbour Mice and HBICE [9][10] - Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, focuses on innovative biological and small molecule drugs, with over 30 ongoing projects, including a leading proprietary ADC platform, OptiDC™ [12] Market Opportunity - WIN378 targets approximately 5 million advanced, uncontrolled patients with severe asthma and COPD in the US, Europe, and Japan [2] - The company aims to address unmet needs in immunological diseases through its lead program and bispecific pipeline, leveraging validated targets and synergistic biology [7][8]